Gracell Biotechnologies Reports Fourth Quarter and Full Year 2022 Unaudited Financial Results, and Provides Corporate Update
GRCLDelisted Stock | USD 4.02 0.26 6.07% |
About 62% of Gracell Biotechnologies' investor base is looking to short. The analysis of current outlook of investing in Gracell Biotechnologies suggests that many traders are alarmed regarding Gracell Biotechnologies' prospects. Gracell Biotechnologies' investing sentiment shows overall attitude of investors towards Gracell Biotechnologies.
Gracell |
Plan to commence Phase 1b2 clinical trial in US evaluating FasTCAR-T GC012F for the treatment of relapsedrefractory multiple myeloma in the second...
Read at globenewswire.com
Gracell Biotechnologies Fundamental Analysis
We analyze Gracell Biotechnologies' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gracell Biotechnologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gracell Biotechnologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Target Price
Target Price Comparative Analysis
Gracell Biotechnologies is currently under evaluation in target price category among its peers.
Gracell Biotechnologies Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Gracell Biotechnologies stock to make a market-neutral strategy. Peer analysis of Gracell Biotechnologies could also be used in its relative valuation, which is a method of valuing Gracell Biotechnologies by comparing valuation metrics with similar companies.
Peers
Gracell Biotechnologies Related Equities
GLUE | Monte Rosa | 13.72 | ||||
XFOR | X4 Pharmaceuticals | 11.43 | ||||
CTMX | CytomX Therapeutics | 3.92 | ||||
BOLT | Bolt Biotherapeutics | 1.59 | ||||
DAWN | Day One | 1.53 | ||||
BPMC | Blueprint Medicines | 1.35 | ||||
ASMB | Assembly Biosciences | 1.25 | ||||
SPRO | Spero Therapeutics | 0.88 | ||||
DSGN | Design Therapeutics | 0.50 | ||||
ABOS | Acumen Pharmaceuticals | 0.44 | ||||
INZY | Inozyme Pharma | 0.37 | ||||
TERN | Terns Pharmaceuticals | 1.58 | ||||
ERAS | Erasca | 2.05 | ||||
NXTC | NextCure | 2.50 | ||||
CHRS | Coherus BioSciences | 3.17 | ||||
AMLX | Amylyx Pharmaceuticals | 3.48 |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Other Consideration for investing in Gracell Stock
If you are still planning to invest in Gracell Biotechnologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gracell Biotechnologies' history and understand the potential risks before investing.
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |